{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:28:27Z","timestamp":1785932907179,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2000,1]]},"DOI":"10.1378\/chest.117.1.14","type":"journal-article","created":{"date-parts":[[2003,6,14]],"date-time":"2003-06-14T00:09:19Z","timestamp":1055549359000},"page":"14-18","source":"Crossref","is-referenced-by-count":100,"title":["Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus"],"prefix":"10.1016","volume":"117","author":[{"given":"Ivan M.","family":"Robbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Loyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.117.1.14_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.CIR.42.6.1163","article-title":"Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 diagnosed cases","volume":"42","author":"Wagenvoort","year":"1970","journal-title":"Circulation"},{"key":"10.1378\/chest.117.1.14_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/01.CIR.18.4.533","article-title":"The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects","volume":"18","author":"Heath","year":"1958","journal-title":"Circulation"},{"key":"10.1378\/chest.117.1.14_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00291151","article-title":"Pulmonary hypertension in connective tissue disease: report of three cases and review of the literature","volume":"11","author":"Pronk","year":"1991","journal-title":"Rheumatol Int"},{"key":"10.1378\/chest.117.1.14_bib4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0002-9343(78)90455-2","article-title":"Pulmonary vascular changes in scleroderma","volume":"64","author":"Young","year":"1978","journal-title":"Am J Med"},{"key":"10.1378\/chest.117.1.14_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-86-4-394","article-title":"Pulmonary hypertension in CREST syndrome variant of progressive systemic sclerosis (scleroderma)","volume":"86","author":"Salerni","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.117.1.14_bib6","first-page":"1292","article-title":"Pulmonary hypertension in a lupus clinic: experience with twenty-four patients","volume":"17","author":"Asherson","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1378\/chest.117.1.14_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/000331978503600705","article-title":"Cardiovascular manifestations in systemic lupus erythematosus: prospective study of 100 patients","volume":"36","author":"Badui","year":"1985","journal-title":"Angiology"},{"key":"10.1378\/chest.117.1.14_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0049-0172(81)90098-6","article-title":"Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature","volume":"11","author":"Perez","year":"1981","journal-title":"Semin Arthritis Rheum"},{"key":"10.1378\/chest.117.1.14_bib9","first-page":"284","article-title":"Pulmonary vascular disease in systemic lupus erythematosus","volume":"65","author":"Fayemi","year":"1976","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.117.1.14_bib10","first-page":"918","article-title":"Pulmonary hypertension in systemic lupus erythematosus","volume":"16","author":"Simonson","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1378\/chest.117.1.14_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.117.1.14_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.117.1.14_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"334","author":"McLaughlin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.117.1.14_bib14","first-page":"A630","article-title":"Use of epoprostenol in secondary pulmonary hypertension [abstract]","volume":"155","author":"Baba","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.117.1.14_bib15","doi-asserted-by":"crossref","first-page":"80S","DOI":"10.1378\/chest.114.1_Supplement.80S","article-title":"Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin)","volume":"114","author":"Humbert","year":"1998","journal-title":"Chest"},{"key":"10.1378\/chest.117.1.14_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.117.1.14_bib17","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.117.1.14_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0889-857X(21)00230-1","article-title":"Pleuropulmonary manifestations of systemic lupus erythematosus","volume":"20","author":"Orens","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1378\/chest.117.1.14_bib19","first-page":"1078","article-title":"Primary pulmonary hypertension and SLE","volume":"88","author":"Cummings","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.117.1.14_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archinte.1984.00350150217042","article-title":"Systemic lupus erythematosus and pulmonary vascular hypertension","volume":"144","author":"Schwartzberg","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.117.1.14_bib21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/00007611-197908000-00037","article-title":"Severe pulmonary vascular disease in systemic lupus erythematosus","volume":"72","author":"Sack","year":"1979","journal-title":"South Med J"},{"key":"10.1378\/chest.117.1.14_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archinte.1980.00330130111026","article-title":"Pulmonary hypertension and systemic lupus erythematosus","volume":"140","author":"Nair","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.117.1.14_bib23","first-page":"1","article-title":"Pulmonary hypertension and systemic lupus erythematosus","volume":"13","author":"Asherson","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1378\/chest.117.1.14_bib24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7326\/0003-4819-122-12-199506150-00009","article-title":"Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease","volume":"122","author":"Boumpas","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.117.1.14_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-112-9-682","article-title":"Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance","volume":"112","author":"Love","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.117.1.14_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.117.1.14_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1378\/chest.88.1.129","article-title":"Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its sub-groups, prognostic and therapeutic implications","volume":"88","author":"Pines","year":"1985","journal-title":"Chest"},{"key":"10.1378\/chest.117.1.14_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1378\/chest.114.5.1269","article-title":"A survey of diagnostic practices and the use of epoprostenol in primary pulmonary hypertension","volume":"114","author":"Robbins","year":"1998","journal-title":"Chest"},{"key":"10.1378\/chest.117.1.14_bib29","first-page":"A158","article-title":"Survival in pulmonary hypertension associated with connective tissue disease (PH-CTD) treated long-term epoprostenol (PGI2): comparison with primary pulmonary hypertension [abstract]","volume":"159","author":"Sitbon","year":"1999","journal-title":"Am Rev Respir Crit Care"},{"key":"10.1378\/chest.117.1.14_bib30","first-page":"I","article-title":"Continuous intravenous epoprostenol versus conventional therapy in pulmonary hypertension due to the scleroderma spectrum of disease: A 12-week, multicenter, randomized trial [abstract]","volume":"98","author":"Badesch","year":"1998","journal-title":"Circulation"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215309223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215309223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:09:46Z","timestamp":1734041386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215309223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["S0012369215309223"],"URL":"https:\/\/doi.org\/10.1378\/chest.117.1.14","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}